AFT PHARMACEUTICALS LIMITED
ASX:AFPPharmaceuticals, Biotechnology & Life SciencesToday’s holders own 99.4% of what they think they own, once every option and right converts.
No issuance filings since 2024; no dilution pressure signals in current disclosures
As of June 2026, its latest share-count filing, AFT PHARMACEUTICALS LIMITED had 105M ordinary shares on issue. The company has not lodged a new share-issuance filing since January 2024, so no comparative share-count figure is available. No capital raising placements, rights issues or share purchase plans have occurred in the past 24 months. Options and rights on issue could convert into 651,000 new shares, equal to 0.6% of the current share count, none of which are in the money; no filing on record states an expiry date for these securities. No quarterly or half-year/annual cash report runway figure is on record. No proposed securities issues are pending.
Quick answers · 2
How much placement capacity does AFP have left?
None of the 15% placement capacity counted as used in the last 12 months (estimate). Under ASX Listing Rule 7.1 a company may place up to 15% of its shares in 12 months without shareholder approval.
How many options and rights does AFP have outstanding?
Unexercised options and rights equal 0.6% of Aft Pharmaceuticals's shares on issue.
Shares on issue — last 2 years
Cash runway
Issuance timeline
Latest 1 filings (Appendix 2AThe form a company lodges to have new securities quoted on the ASX. It restates how many of each class are on issue. quoted issues, 3G unquoted, 3H cancellations)
| Date | Form | Security | On issue, per this filing | Source |
|---|---|---|---|---|
| 22 June 2026 | 2A · quoted issue | AFP : ORDINARY FULLY PAID FOREIGN EXEMPT NZX | 104.9M | Appendix 2A |
Securities on issue over time
Ordinary shares and every option and rights class, month by month over two years. The top edge is the fully diluted count.
Capital raises
Forward supply
Every dated event on record that could add securities to the register — option expiries to their stated dates and proposed issues over the next 18 months, on one timeline.
Placement capacity
How much stock a company can place without asking holders. Listing Rule 7.1 / 7.1ARule 7.1 lets a company issue up to 15% of its shares in 12 months without a shareholder vote. Rule 7.1A adds 10% for smaller companies whose holders approve it. allows 15% of ordinary securities in any 12 months, and every Appendix 3BNotice that a company proposes to issue new securities, such as a placement. The securities are not on issue until a later filing confirms it. states how much of it an issue uses.
Pending proposed issues
Options & convertible securities
No option supply on record carries an exercise price to pay, so no share price switches any of it on. All 651k of it converts on something else — a hurdle that may never be met, or terms the filing does not price.
| Code | Security | Type | Exercise price | Expiry | On issue | Source |
|---|---|---|---|---|---|---|
| AFPAB | Options | Price-triggered, no exercise price stated | — | — | 651k | Filing |
“Nil” is a stated nil exercise price: nothing is paid to convert. An em dash means the filing names no exercise price at all. Security is read from the filing’s own class description; an em dash there means the description is not one this table labels. One row is one security class, at the number stated in the most recent quotation application that restated it — linked, and dated, in the last column. For what expires soon across other listed companies, see the options expiry calendar.
Director dealings
Ownership
Latest announcements
Headlines link to the source PDFs on the ASX announcements platform. Data as of 28 Oct 2026.